SE0104330D0 - Therapeutic agents - Google Patents

Therapeutic agents

Info

Publication number
SE0104330D0
SE0104330D0 SE0104330A SE0104330A SE0104330D0 SE 0104330 D0 SE0104330 D0 SE 0104330D0 SE 0104330 A SE0104330 A SE 0104330A SE 0104330 A SE0104330 A SE 0104330A SE 0104330 D0 SE0104330 D0 SE 0104330D0
Authority
SE
Sweden
Prior art keywords
sub
sup
group
optionally substituted
alkyl
Prior art date
Application number
SE0104330A
Other languages
English (en)
Swedish (sv)
Inventor
Kristina Berggren
Jonas Bostroem
Thomas Elebring
Peter Greasley
Emma Terricabras
Michael Wilstermann
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0104330A priority Critical patent/SE0104330D0/xx
Publication of SE0104330D0 publication Critical patent/SE0104330D0/xx
Priority to HU0402026A priority patent/HUP0402026A3/hu
Priority to AU2002352425A priority patent/AU2002352425A1/en
Priority to US10/499,054 priority patent/US7342019B2/en
Priority to DE60218340T priority patent/DE60218340T2/de
Priority to PCT/GB2002/005742 priority patent/WO2003051851A1/en
Priority to AT02788143T priority patent/ATE354570T1/de
Priority to IL16237702A priority patent/IL162377A0/xx
Priority to MXPA04005990A priority patent/MXPA04005990A/es
Priority to ES02788143T priority patent/ES2280599T3/es
Priority to EP02788143A priority patent/EP1458690B1/de
Priority to CNA028281535A priority patent/CN1620438A/zh
Priority to KR10-2004-7009589A priority patent/KR20040068286A/ko
Priority to NZ533275A priority patent/NZ533275A/en
Priority to BR0214989-3A priority patent/BR0214989A/pt
Priority to CA002469786A priority patent/CA2469786A1/en
Priority to RU2004116916/04A priority patent/RU2004116916A/ru
Priority to PL02369731A priority patent/PL369731A1/xx
Priority to JP2003552736A priority patent/JP2005517655A/ja
Priority to TW091136671A priority patent/TW200410694A/zh
Priority to ARP020105001A priority patent/AR038044A1/es
Priority to IS7314A priority patent/IS7314A/is
Priority to ZA200404805A priority patent/ZA200404805B/en
Priority to CO04065292A priority patent/CO5590917A2/es
Priority to NO20043022A priority patent/NO20043022L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE0104330A 2001-12-19 2001-12-19 Therapeutic agents SE0104330D0 (sv)

Priority Applications (25)

Application Number Priority Date Filing Date Title
SE0104330A SE0104330D0 (sv) 2001-12-19 2001-12-19 Therapeutic agents
JP2003552736A JP2005517655A (ja) 2001-12-19 2002-12-18 Ｃｂ１アンタゴニストとしての５，６−ジアリール−ピラジン−２−アミド誘導体
EP02788143A EP1458690B1 (de) 2001-12-19 2002-12-18 5,6-diaryl-pyrazineamidderivate als cb1 antagonisten
KR10-2004-7009589A KR20040068286A (ko) 2001-12-19 2002-12-18 Ｃｂ１ 길항물질로서의 5,6-디아릴-피라진-2-아미드 유도체
US10/499,054 US7342019B2 (en) 2001-12-19 2002-12-18 5, 6-diaryl-pyrazine-2-amide derivatives as CB1 antagonists
DE60218340T DE60218340T2 (de) 2001-12-19 2002-12-18 5,6-diaryl-pyrazineamidderivate als cb1 antagonisten
PCT/GB2002/005742 WO2003051851A1 (en) 2001-12-19 2002-12-18 5, 6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists
AT02788143T ATE354570T1 (de) 2001-12-19 2002-12-18 5,6-diaryl-pyrazineamidderivate als cb1 antagonisten
IL16237702A IL162377A0 (en) 2001-12-19 2002-12-18 5,6-Diaryl-pyrazine-2-amide derivatives as cb1 antagonists
MXPA04005990A MXPA04005990A (es) 2001-12-19 2002-12-18 Derivados de 5,6-diaril-pirazina-2-amida como antagonistas de cb1.
ES02788143T ES2280599T3 (es) 2001-12-19 2002-12-18 Derivados de 5,6-diaril-pirazin-2-amida como antagonistas de cb1.
HU0402026A HUP0402026A3 (en) 2001-12-19 2002-12-18 5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists, process for their preparation and pharmaceutical compositions containing them
CNA028281535A CN1620438A (zh) 2001-12-19 2002-12-18 用作cbi拮抗剂的5,6－二芳基－吡嗪－2－酰胺衍生物
AU2002352425A AU2002352425A1 (en) 2001-12-19 2002-12-18 5,6-diaryl-pyrazine-2-amide derivatives as CB1 antagonists
NZ533275A NZ533275A (en) 2001-12-19 2002-12-18 5, 6-Diaryl-pyrazine-2-amide derivatives as CB1 antagonists
BR0214989-3A BR0214989A (pt) 2001-12-19 2002-12-18 Composto, formulação farmacêutica, uso de um composto, método de tratamento de doenças, e, processo para a preparação de um composto
CA002469786A CA2469786A1 (en) 2001-12-19 2002-12-18 5, 6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists
RU2004116916/04A RU2004116916A (ru) 2001-12-19 2002-12-18 Производные 5,6-биарил-пиразин-2-амида в качестве антагонистов cb1
PL02369731A PL369731A1 (en) 2001-12-19 2002-12-18 5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists
ARP020105001A AR038044A1 (es) 2001-12-19 2002-12-19 Compuesto derivado de pirazina, composicion farmaceutica, su uso en la fabricacion de un medicamento, proceso para su preparacion y compuesto intermediario en dicho proceso.
TW091136671A TW200410694A (en) 2001-12-19 2002-12-19 Therapeutic agents
IS7314A IS7314A (is) 2001-12-19 2004-06-16 5,6-díarýl-pýrasín-2-amíðafleiður sem cb1 mótlyf
ZA200404805A ZA200404805B (en) 2001-12-19 2004-06-17 5,6-diaryl-pyrazine-2-amide derivatives as CB1 antagonists.
CO04065292A CO5590917A2 (es) 2001-12-19 2004-07-09 Derivados de 5,6-diaril-pirazina-2-amida como antagonistas cb1
NO20043022A NO20043022L (no) 2001-12-19 2004-07-15 5,6-diaryl-pyrazin-2-amid-derivater som CB1-antagonister

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0104330A SE0104330D0 (sv) 2001-12-19 2001-12-19 Therapeutic agents

Publications (1)

Publication Number Publication Date
SE0104330D0 true SE0104330D0 (sv) 2001-12-19

Family

ID=20286429

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0104330A SE0104330D0 (sv) 2001-12-19 2001-12-19 Therapeutic agents

Country Status (25)

Country Link
US (1) US7342019B2 (de)
EP (1) EP1458690B1 (de)
JP (1) JP2005517655A (de)
KR (1) KR20040068286A (de)
CN (1) CN1620438A (de)
AR (1) AR038044A1 (de)
AT (1) ATE354570T1 (de)
AU (1) AU2002352425A1 (de)
BR (1) BR0214989A (de)
CA (1) CA2469786A1 (de)
CO (1) CO5590917A2 (de)
DE (1) DE60218340T2 (de)
ES (1) ES2280599T3 (de)
HU (1) HUP0402026A3 (de)
IL (1) IL162377A0 (de)
IS (1) IS7314A (de)
MX (1) MXPA04005990A (de)
NO (1) NO20043022L (de)
NZ (1) NZ533275A (de)
PL (1) PL369731A1 (de)
RU (1) RU2004116916A (de)
SE (1) SE0104330D0 (de)
TW (1) TW200410694A (de)
WO (1) WO2003051851A1 (de)
ZA (1) ZA200404805B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704995B2 (en) 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
EP1546115A4 (de) 2002-09-27 2010-08-04 Merck Sharp & Dohme Substituierte pyrimidine
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
GB0230088D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302673D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
JP2006527770A (ja) * 2003-06-18 2006-12-07 アストラゼネカ アクチボラグ Ｃｂ１モジュレーターとしての２−置換５，６−ジアリール−ピラジン誘導体
GB0314049D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314057D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314261D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
US7276608B2 (en) 2003-07-11 2007-10-02 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US7326706B2 (en) * 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
WO2005020992A1 (en) * 2003-09-02 2005-03-10 Solvay Pharmaceuticals Gmbh Novel medical use of selective cb1-receptor antagonists
US7320805B2 (en) * 2003-10-01 2008-01-22 Institut National De La Sante Et De La Recherche Medicale CB2 receptors blocks accumulation of human hepatic myofibroblasts: a novel artifibrogenic pathway in the liver
EP1670460B1 (de) 2003-10-10 2014-11-26 Bristol-Myers Squibb Company Pyrazol-derivate als cannabinoid-rezeptor-modulatoren
EP1680116A1 (de) * 2003-10-24 2006-07-19 Solvay Pharmaceuticals GmbH Kombinationsbehandlung von adipositas mit selektiven cb1-antagonisten und lipasehemmern
TW200528102A (en) * 2003-10-24 2005-09-01 Solvay Pharm Gmbh Novel medical combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
GB0327331D0 (en) * 2003-11-25 2003-12-31 Astrazeneca Ab Therapeutic agents
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
MX2007004889A (es) 2004-10-25 2007-09-11 Solvay Pharm Gmbh Composiciones farmaceuticas que comprenden antagonistas del receptor cannabinoide cb1 y activadores de canales de potasio para el tratamiento de la diabetes mellitus tipo i, la obesidad y trastornos relacionados.
BRPI0609685A2 (pt) 2005-04-06 2010-04-20 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para tratamento e/ou profilaxia de enfermidades que estão associados com a modulação de receptores de cb1, e utilização dos mesmos
AR053712A1 (es) * 2005-04-18 2007-05-16 Neurogen Corp Heteroarilos sustituidos, antagonistas de cb1 (receptor 1 canabinoide)
NZ564759A (en) 2005-06-30 2011-08-26 Prosidion Ltd GPCR agonists
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
RU2454405C2 (ru) * 2006-10-04 2012-06-27 Ф.Хоффманн-Ля Рош Аг Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина
WO2008081208A1 (en) 2007-01-04 2008-07-10 Prosidion Limited Piperidine gpcr agonists
BRPI0806498A2 (pt) 2007-01-04 2014-04-22 Prosidion Ltd Agonistas gpcr piperidina
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
AR064736A1 (es) 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr
CL2008000018A1 (es) 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
US9403808B2 (en) * 2011-10-28 2016-08-02 Hoffmann-La Roche Inc. Pyrazine derivatives
AU2021322253A1 (en) 2020-08-06 2023-02-23 Chdi Foundation, Inc. Heterobiaryl compounds and imaging agents for imaging Huntingtin protein
PY2404093A (es) * 2023-01-30 2024-10-03 Eurofarma Laboratorios S A Hidrazidas bloqueadoras de nav 1.7 y/o nav 1.8, sus procesos de obtención, composiciones, usos, métodos de tratamiento de los mismos y kits
PY2404641A (es) * 2023-01-30 2024-10-03 Eurofarma Laboratorios S A COMPUESTOS FENÓLICOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, SUS COMPOSICIONES, SUS USOS, LOS MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y SUS KITS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH458361A (de) * 1965-01-15 1968-06-30 Eprova Ag Verfahren zur Herstellung von Pyrazincarbonsäuren
JPS5322529A (en) * 1976-08-13 1978-03-02 Nippon Soda Co Ltd Dihydropyrazine derivative and its preparation
EP0397859A4 (en) * 1987-11-12 1990-12-19 Terumo Kabushiki Kaisha Pyrazine derivatives and medicinal preparation containing same
JPH06501926A (ja) * 1990-08-06 1994-03-03 藤沢薬品工業株式会社 複素環式化合物
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.

Also Published As

Publication number Publication date
IL162377A0 (en) 2005-11-20
JP2005517655A (ja) 2005-06-16
PL369731A1 (en) 2005-05-02
MXPA04005990A (es) 2004-09-27
KR20040068286A (ko) 2004-07-30
EP1458690B1 (de) 2007-02-21
BR0214989A (pt) 2004-12-14
AR038044A1 (es) 2004-12-22
DE60218340D1 (de) 2007-04-05
HUP0402026A3 (en) 2005-08-29
ATE354570T1 (de) 2007-03-15
NO20043022L (no) 2004-07-15
EP1458690A1 (de) 2004-09-22
NZ533275A (en) 2006-02-24
ES2280599T3 (es) 2007-09-16
WO2003051851A1 (en) 2003-06-26
CA2469786A1 (en) 2003-06-26
US20050032808A1 (en) 2005-02-10
US7342019B2 (en) 2008-03-11
AU2002352425A1 (en) 2003-06-30
CO5590917A2 (es) 2005-12-30
IS7314A (is) 2004-06-16
ZA200404805B (en) 2005-08-15
HUP0402026A2 (hu) 2005-02-28
CN1620438A (zh) 2005-05-25
DE60218340T2 (de) 2007-11-29
RU2004116916A (ru) 2005-11-10
TW200410694A (en) 2004-07-01

Similar Documents

Publication Publication Date Title
MXPA04005990A (es) Derivados de 5,6-diaril-pirazina-2-amida como antagonistas de cb1.
TW200503692A (en) Therapeutic agents
TW200507839A (en) Therapeutic agents
WO2004020431A3 (en) Novel benzoimidazole derivatives useful as antiproliferative agents
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
NO20055421L (no) Kinolinderivater som fosfodiestrase-inhibitorer
SE0104332D0 (sv) Therapeutic agents
WO2002089782A3 (en) Dioxanes and uses thereof
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
PT842923E (pt) Derivados do pirrolo e composicoes medicinais
PL353646A1 (en) Aminobenzophenones as inhibitors of il-1beta and tnf-alpha
AU8799201A (en) Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases
EA200501703A1 (ru) Применение производных азетидинкарбоксамида в терапии
SI1210320T1 (en) Aminobenzophenones as inhibitors of il-1beta and tnf-alpha
AR044830A1 (es) Derivados de 4,5 diaril -3-heterociclilpirazin- 2- ester
IL148875A0 (en) Sulfonyl hydrazide derivatives, their preparation and pharmaceutical compositions containing them
CA2345069A1 (en) 2-phenylpyran-4-one derivatives
DE69512816D1 (de) Oxopyridylchinoxalin Derivate
DE69828197D1 (de) Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut
DE60226971D1 (de) Corticotropinfreisetzungsfaktor antagonisten
EP0183369A3 (de) Dihydroisochinolinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
GB0327331D0 (en) Therapeutic agents
WO2005007630A3 (en) Aryl fused azapolycyclic compounds
ATE409698T1 (de) 1,2,4-triazolderivat, verfahren zu dessen herstellung, und dieses enthaltende pharmazeutische zusammensetzung
MXPA02012072A (es) Derivados de 4,5-dihidro-tiazol-2-ilamina y su uso como inhibidores de no-sintasa.